|
2008/07/13 (日) 22:50 <font color=#003399><a href=http://www.drugs.com/news>LONDON, June 13, 2008-The European Medicines</a> power (EMEA) ahs recommended updating the yield dirt for epoetin-containing medicines with a new indication for their use in cancer patients stating that blood transfusion should be the preferred method of correcting anaemia in patients hardship cancer.
pEoetin-containing medicines are indicated in patients with <a href=http://www.blogotop.com/acheterviagra>acheter levitra generique</a> non-starter and for the treatment of anaemia in symptomatic patients with non-myeloid growths receiving chemotherapy. The power痴 cabinet for reemedial Products for Good Samaritan Use (CHMP) had noticed new details from studies that showed an increased hazard of sarcoma <a href=http://www.blogotop.com/acheterviagra>achat cialis generique</a> movement forward, venous thromboembolism and shorter inclusive <a href=http://www.google.com/search?hl=en&q=survival+in+cancer+patients&btnG=Google+Search>survival in cancer patients</a> who experienced epoetins compared to patients who did not admit them. Following this periodical, the CHMP concluded, at its June 2008 union, that the gains of epoetins procovet surpass their endangers in the approved indications. after all, in cancer patients with a reasonably lengthy existence-expectancy, the improve of using epoetins does not surpass the endanger growth ascension and shorter all-inclusive survival and for that reason the board concluded that in these patients anaemia should be correctfed with blood transfusions. </font>
|